{"prompt": "['REFERENCES (26-APR-2019)', 'Anscher, M.S., R. Clough, and R. Dodge, Radiotherapy for a rising prostate-specific antigen', 'after radical prostatectomy: the first 10 years. int J Radiat Oncol Biol Phys, 2000. 48(2):', 'p. 369-75.', 'Arcangeli, G., et al., Acute and late toxicity in a randomized trial of conventional versus', 'hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J', 'Radiat Oncol Biol Phys, 2011. 79(4): p. 1013-21.', 'Arcangeli, S., et al., Updated results and patterns of. failure in a randomized hypofractionation', 'trial for high-risk prostate cancer. int J Radiat Oncol Biol Phys, 2012. 84(5): p. 1172-8.', 'Barry, M.J., Quality of life and prostate cancer treatment. J Urol, 1999. 162(2): p. 407.', 'Bentzen, S.M., et al., The UK Standardisation of Breast Radiotherapy (START) Trial A of', 'radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.', 'Lancet Oncol, 2008. 9(4): p. 331-41.', 'Bentzen, S.M., et al., The UK Standardisation of Breast Radiotherapy (START) Trial B of', 'radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.', 'Lancet, 2008. 371(9618): p. 1098-107.', 'Bernard, J.R., Jr., et al., Salvage radiotherapy for rising prostate-specific antigen levels after', 'radical prostatectomy for prostate cancer: dose-response analysis. int J Radiat Oncol', 'Biol Phys, 2010. 76(3): p. 735-40.', 'Bolla, M., Adjuvant or Immediate External Irradiation After Radical Prostatectomy with Pelvic', 'Lymph Node Dissection for High-Risk Prostate Cancer: A Multidisciplinary Decision.', 'Eur Urol, 2012.', 'Bolla, M., et al., Postoperative radiotherapy after radical prostatectomy for high-risk prostate', 'cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet,', '2012. 380(9858): p. 2018-27.', 'Bolla, M., et al., Postoperative radiotherapy after radical prostatectomy: a randomised', 'controlled trial (EORTC trial 22911). Lancet, 2005. 366(9485): p. 572-8.', 'Brenner, D.J., Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys, 2004. 60(4):', 'p. 1013-5.', 'Buyyounouski, M.K., et al., Validating the interval to biochemical failure for the identification', 'of potentially lethal prostate cancer. J Clin Oncol, 2012. 30(15): p. 1857-63.', 'Coen, J.J., et al., Radical radiation for localized prostate cancer. local persistence of disease', 'results in a late wave of metastases. J Clin Oncol, 2002. 20(15): p. 3199-205.', 'Cox DR. Regression models and life tables. Journal of the Royal Statistical Society 1972;34:187-', 'NRG-GU003', '49', 'Version Date: April 26, 2019']['202.', 'Cozzarini, C., et al., Need for high radiation dose (>or=70 gy) in early postoperative irradiation', 'after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative', 'patients. int J Radiat Oncol Biol Phys, 2009. 75(4): p. 966-74.', 'De Meerleer, G., et al., Salvage intensity-modulated radiotherapy for rising PSA after radical', 'prostatectomy. Radiother Oncol, 2008. 89(2): p. 205-13.', 'Dearnaley, D.P., et al., Escalated-dose versus standard-dose conformal radiotherapy in prostate', 'cancer: first results from the MRC RT0I randomised controlled trial. Lancet Oncol,', '2007. 8(6): p. 475-87.', 'Fairclough DL, Peterson HF, Cella D, Bonomi P. Comparison of several model-based methods', 'for analysing incomplete quality of life data in cancer clinical trials. Stat Med. Mar 15-', 'Apr 15 1998;17(5-7):781-796.', 'Fairclough D. Design and analysis of quality of life studies in clinical trials (2nd ed.). Boca', 'Raton, FL: Chapman & Hall/CRC; 2010.', 'Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A. Long-term', 'androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer', 'patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol', 'Biol Phys. 2005 Jun 62(2):397-405.', 'Feng, M., et al., Predictive factors for late genitourinary and gastrointestinal toxicity in patients', 'with prostate cancer treated with adjuvant or salvage radiotherapy. int J Radiat Oncol', 'Biol Phys, 2007. 68(5): p. 1417-23.', 'Fine J, Gray R. A proportional hazards model for the subditribution of a competing risk. J Am', 'Statist Assoc. 1999;94:496-509.', 'Freedland SJ. Adjuvant and salvage radiotherapy after prostatectomy: American Society of', 'Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2014 Dec', '1;32(34):3892-8. Epub 2014 Nov 3.', 'Freidlin, B., E.L. Korn, and Gray, R. A general inefficacy interim monitoring rule for', 'randomized clinical trials. Clin Trials, 2010. 7: p. 197-208.', 'Fuks, Z., et al., The effect of local control on metastatic dissemination in carcinoma of the', 'prostate: long-term results in patients treated with 1251 implantation. int J Radiat Oncol', 'Biol Phys, 1991.21(3):p. 537-47.', 'Ghia, A.J., D.C. Shrieve, and J.D. Tward, Adjuvant radiotherapy use and patterns of care', 'analysis for margin-positive prostate adenocarcinoma with extracapsular extension:', 'post-prostatectomy adjuvant radiotherapy: a SEER analysis. Urology, 2010. 76(5): p.', '1169-74.', 'NRG-GU003', '50', 'Version Date: April 26, 2019']\n\n###\n\n", "completion": "END"}